

LIFELINE THERAPEUTICS, INC.

Form 8-K

May 16, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 15, 2006

**Lifeline Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Colorado**

**000-30489**

**84-1097796**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6400 South Fiddler s Green Circle, Suite 1970, Englewood, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (720) 488-1711

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition**

On May 15, 2006, Lifeline Therapeutics, Inc. issued a press release entitled Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results. The press release is attached as Exhibit 99.1 hereto.

**Item 7.01 Regulation FD Disclosure**

On May 15, 2006, Lifeline Therapeutics, Inc. issued a press release entitled Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results. The press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Exhibits**

99.1 Press release, dated May 15, 2006, entitled Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 16, 2006

LIFELINE THERAPEUTICS, INC.

By: /s/ Stephen K. Onody  
Stephen K. Onody  
Chief Executive Officer

**Exhibit Index**

**Exhibit**

**Number**

**Description**

99.1 Press release, dated May 15, 2006, entitled Lifeline Therapeutics, Inc. Announces Q3 FY 2006 Financial and Operating Results.